4//SEC Filing
Khan Najat 4
Accession 0001628280-25-004086
CIK 0001601830other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:50 PM ET
Size
11.7 KB
Accession
0001628280-25-004086
Insider Transaction Report
Form 4
Khan Najat
DirectorChief R&D Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-02-03+420,226→ 420,226 totalExercise: $7.25Exp: 2035-02-03→ Class A Common Stock (420,226 underlying) - Award
Class A Common Stock
2025-02-03+210,113→ 707,085 total - Award
Class A Common Stock
2025-02-03+8,049→ 715,134 total - Tax Payment
Class A Common Stock
2025-02-03$7.25/sh−2,753$19,959→ 712,381 total
Holdings
- 993,944
Stock Option (Right to Buy)
Exercise: $7.34Exp: 2034-08-01→ Class A Common Stock (0 underlying)
Footnotes (5)
- [F1]This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter.
- [F2]This RSU vested immediately upon the grant date.
- [F3]Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- [F4]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F5]This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0002020969
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:50 PM ET
- Size
- 11.7 KB